These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28254822)

  • 1. Immune reconstitution and remission in CML.
    Scheinberg DA
    Blood; 2017 Mar; 129(9):1064-1065. PubMed ID: 28254822
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon.
    Oka T; Sastry KJ; Nehete P; Schapiro SJ; Guo JQ; Talpaz M; Arlinghaus RB
    Leukemia; 1998 Feb; 12(2):155-63. PubMed ID: 9519777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.
    Chen CI; Koschmieder S; Kerstiens L; Schemionek M; Altvater B; Pscherer S; Gerss J; Maecker HT; Berdel WE; Juergens H; Lee PP; Rossig C
    Leukemia; 2012 Mar; 26(3):465-74. PubMed ID: 21904381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib.
    Clapp GD; Lepoutre T; El Cheikh R; Bernard S; Ruby J; Labussière-Wallet H; Nicolini FE; Levy D
    Cancer Res; 2015 Oct; 75(19):4053-62. PubMed ID: 26359456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
    Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
    Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-free remission and immunity in chronic myeloid leukemia.
    Ureshino H
    Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of autologous natural killer cells in chronic myelogenous leukemia.
    Pierson BA; Miller JS
    Leuk Lymphoma; 1997 Nov; 27(5-6):387-99. PubMed ID: 9477121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.
    Wu CJ; Yang XF; McLaughlin S; Neuberg D; Canning C; Stein B; Alyea EP; Soiffer RJ; Dranoff G; Ritz J
    J Clin Invest; 2000 Sep; 106(5):705-14. PubMed ID: 10974024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.
    Inselmann S; Wang Y; Saussele S; Fritz L; Schütz C; Huber M; Liebler S; Ernst T; Cai D; Botschek S; Brendel C; Calogero RA; Pavlinic D; Benes V; Liu ET; Neubauer A; Hochhaus A; Burchert A
    Cancer Res; 2018 Nov; 78(21):6223-6234. PubMed ID: 30166420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.
    Watanabe T; Hotta C; Koizumi S; Miyashita K; Nakabayashi J; Kurotaki D; Sato GR; Yamamoto M; Nakazawa M; Fujita H; Sakai R; Fujisawa S; Nishiyama A; Ikezawa Z; Aihara M; Ishigatsubo Y; Tamura T
    Cancer Res; 2013 Nov; 73(22):6642-53. PubMed ID: 24242069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
    Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.
    Chu S; McDonald T; Lin A; Chakraborty S; Huang Q; Snyder DS; Bhatia R
    Blood; 2011 Nov; 118(20):5565-72. PubMed ID: 21931114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
    Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
    Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI).
    Gozzetti A; Tozzuoli D; Crupi R; Gentili S; Bocchia M; Raspadori D; Lauria F
    Eur J Haematol; 2003 Oct; 71(4):313-4. PubMed ID: 12950245
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft.
    Corsetti MT; Lerma E; Dejana A; Cavaliere M; Figari O; Vassallo F; Abate M; Luchetti S; Piaggio G; Parodi C; Li Pira G; Manca F; Carella AM
    Exp Hematol; 2000 Jan; 28(1):104-11. PubMed ID: 10658682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
    Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.